The Operating System That Makes Every Company Better

If Morgan Stanley’s right, the flying car industry will grow 185,850% by 2050. In fact, they say it will reach $9 trillion in size, more than twice as valuable as today’s global car market. 

And 14,000+ investors believe Doroni will lead the charge. While competitors chase air fleets and taxis, Doroni’s H1-X aircraft is designed for everyday life. 

It plugs in and charges like an EV, fits in a two-car garage, and requires just 25 hours of training to pilot. And while others are peddling blueprints and renderings, Doroni just unveiled a full-scale showroom prototype in March.

They have 600+ pre-orders already locked in, $240M+ in potential revenue in place, and the FAA's regulatory path cleared.

But that's only scratching the surface of why investors are backing Doroni.

With commercial deliveries slated for 2028 and $1.4B in annual revenue projected by 2032, the timing of this raise couldn't be better.

The last time Doroni was open to investors, the opportunity maxed out in less than 100 days. 

And you can claim an early-stage stake in Doroni today. Become a shareholder at $3.30/share.

In the early 1980s, two brothers from Washington, D.C. — Steven and Mitchell Rales — were running a small real estate company called Diversified Mortgage Investors. It wasn’t going well. In 1984, they renamed it Danaher — after a creek in Montana where they loved to fish. They started buying small industrial companies: tools, sensors, instruments. Nobody paid much attention. The companies were unglamorous. The markets were niche. The brothers worked quietly.

Then they discovered the Toyota Production System — the lean manufacturing philosophy that had turned Toyota into the most efficient automaker in the world. The Rales brothers adapted it. They built their own version, calibrated for the kinds of companies they acquired: instruments, diagnostics, life sciences tools. They called it the Danaher Business System — DBS. And for the next four decades, they applied it to every company they bought.

I had blood drawn last month. The nurse labeled the tube, sent it to the lab, and the results appeared on my phone three hours later. I didn’t think about what happened in between. But inside that lab, a machine — likely a Beckman Coulter analyzer — ran the test. It mixed my blood sample with reagents, measured the chemistry, and generated a result. The machine belongs to the hospital. The reagents — the consumables the machine needs to run every test — come from Danaher. The hospital bought the instrument once. It buys the reagents every day.

That is the razor-and-blades model applied to diagnostics. And it runs through nearly every hospital, clinical lab, and reference laboratory in the developed world.

Danaher today is a focused life sciences and diagnostics company. It operates through three segments: Diagnostics — which includes Beckman Coulter, Cepheid, Leica Biosystems, and Radiometer — generated $10.0 billion in revenue in fiscal 2025, with 89% of that revenue classified as recurring. Life Sciences — which includes Leica Microsystems, SCIEX, and other instrumentation businesses — generated $7.3 billion. The remaining revenue comes from the Biotechnology segment, anchored by Cytiva and Pall, which serve the pharmaceutical and bioprocessing industries.

Over the past decade, Danaher has narrowed its focus dramatically. In 2016, it spun off Fortive — its industrial technology businesses. In 2023, it spun off Veralto — its environmental and applied solutions businesses. What remains is the core: the instruments and consumables that run the world’s laboratories.

In fiscal 2025, Danaher reported $24.6 billion in revenue — up 2.9% from the year before, with 2% core revenue growth. Gross profit margin was 59.1%. Adjusted operating profit margin was 28.2%. Free cash flow reached $5.3 billion — marking the 34th consecutive year in which free cash flow exceeded net income. That 34-year streak is one of the longest in corporate America. Rainer Blair, Danaher’s president and CEO, said it plainly in the fiscal 2024 year-end release: “We believe Danaher is better positioned than at any point in our 40-year history.”

Elon Is Quietly Building a Device That Could Kill the iPhone.

See why the government documents, trademarks, and deals all point to Elon's next mega-launch.

That 89% recurring revenue in Diagnostics is the number that explains why the cash flows are so consistent. When a hospital installs a Beckman Coulter hematology analyzer or a Cepheid molecular testing system, the instrument becomes part of the lab’s daily workflow. Every test requires proprietary reagents and consumables — purchased from Danaher. The instrument is the razor. The reagent is the blade. And unlike a razor that you might switch for a cheaper alternative, a clinical instrument’s consumables are designed to work only with that specific machine. You don’t switch mid-test. You don’t shop around for off-brand reagents when a patient is waiting for a diagnosis. You buy from Danaher. Every day. For the life of the instrument.

The stickiness compounds through DBS. When Danaher acquires a company, it doesn’t just write a check and hope. It sends in DBS practitioners — lean experts who study every process, eliminate waste, reduce cycle times, and improve quality. The result: margins expand, customer satisfaction rises, and the acquired company becomes more competitive than it was before the deal. Every acquisition is an opportunity to apply the system. Every application of the system makes the next acquisition more valuable.

The pricing power is structural and largely invisible. Reagent prices rise annually — 2% to 4% — embedded in supply contracts. The customer absorbs the increase because switching instruments is a multi-year, multi-million-dollar undertaking that requires validation, retraining, and regulatory approval. A lab director doesn’t change analyzer platforms because reagents went up 3%. The increase is small enough to accept and large enough to compound.

The flywheel runs on the installed base. Every instrument Danaher places in a lab generates a stream of consumable revenue for years — sometimes a decade or more. As the installed base grows through new instrument placements and acquisitions, the recurring revenue base expands. In fiscal 2025, Diagnostics alone generated $10.0 billion — more than 40% of the company’s total revenue — with 89% of it recurring. That base doesn’t reset each quarter. It accumulates. And DBS ensures that the margin on each dollar of recurring revenue improves over time.

WHY THIS WORKS

Steven and Mitchell Rales named their company after a creek in Montana where they fished. They started with a failing mortgage business, renamed it, and began buying small industrial companies nobody wanted. Then they built an operating system — DBS — and applied it to everything they touched. Forty-two years later, the company named after a fishing creek generates $24.6 billion in revenue from instruments and consumables that run in every hospital lab, every pharmaceutical research center, and every clinical testing facility on earth. The creek still runs through Montana. The system still runs through Danaher. And the reagent — the small, disposable vial that every blood test requires — arrives at the lab every morning, ordered automatically, paid for automatically, and replaced by the next one tomorrow.